354-68-7Relevant articles and documents
Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease
Grand, Darren Le,Gosling, Martin,Baettig, Urs,Bahra, Parmjit,Bala, Kamlesh,Brocklehurst, Cara,Budd, Emma,Butler, Rebecca,Cheung, Atwood K.,Choudhury, Hedaythul,Collingwood, Stephen P.,Cox, Brian,Danahay, Henry,Edwards, Lee,Everatt, Brian,Glaenzel, Ulrike,Glotin, Anne-Lise,Groot-Kormelink, Paul,Hall, Edward,Hatto, Julia,Howsham, Catherine,Hughes, Glyn,King, Anna,Koehler, Julia,Kulkarni, Swarupa,Lightfoot, Megan,Nicholls, Ian,Page, Christopher,Pergl-Wilson, Giles,Popa, Mariana Oana,Robinson, Richard,Rowlands, David,Sharp, Tom,Spendiff, Matthew,Stanley, Emily,Steward, Oliver,Taylor, Roger J.,Tranter, Pamela,Wagner, Trixie,Watson, Hazel,Williams, Gareth,Wright, Penny,Young, Alice,Sandham, David A.
, p. 7241 - 7260 (2021/06/28)
Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel are established as the primary causative factor in the devastating lung disease cystic fibrosis (CF). More recently, cigarette smoke exposure has been shown to be asso
